Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC
Expert urologist explores potential treatments for BCG-unresponsive intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), including immune checkpoint inhibitors, oncolytic viral therapy, cytokine agonists, immunomodulators, and the recently approved drugs pembrolizumab and nogapendekin alfa inbakicept-pmln.
EP: 1.Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC
EP: 2.Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC
EP: 3.Intravesical Novel Therapy for HR BCG-Unresponsive NMIBC
EP: 4.AUA 2024: Outlining BOND-003 Data for NMIBC Therapy
EP: 5.BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment
EP: 6.AUA 2024: Key Takeaways & Future of NMIBC Management
- Can you discuss some of the exploratory treatments for BCG‐unresponsive intermediate and high risk‐NMIBC? (eg. immune checkpoint inhibitors (ICI), oncolytic viral therapy, cytokine agonists, and other immunomodulators)
- BCG‐unresponsiveness (definition?)
- Include (recently) approved immunotherapies: pembrolizumab, nogapendekin alfa inbakicept-pmln
- Gene therapy: nadofaragene firadenovec
Advancing bladder cancer care: The importance of integrating mental health support
September 9th 2024"I think the fact that we're having these conversations, that they are being talked about at national meetings, and that we are bringing the patient voice into this is hugely important," says Mary W. Dunn, MSN, NP-C, OCN, RN.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
